Literature DB >> 7636873

Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics.

M A Eissenstat1, M R Bell, T E D'Ambra, E J Alexander, S J Daum, J H Ackerman, M D Gruett, V Kumar, K G Estep, E M Olefirowicz.   

Abstract

Aminoalkylindoles (AAIs) are a novel series of cannabinoid receptor ligands. In this report we disclose the structural features of AAIs which are important for binding to this receptor as measured by inhibition of binding of [3H]Win 55212-2 (5). Functional activity in the mouse vas deferens is also noted and used to distinguish agonists from potential antagonists. The key structural features for potent cannabinoid activity in this series are a bicyclic (naphthyl) substituent at the 3-position, a small (H) substituent at the 2-position, and an aminoethyl (morpholinoethyl) substituent at the 1-position. A 6-bromo analog, Win 54461 (31), has been identified as a potential cannabinoid receptor antagonist. Modeling experiments were done to develop a pharmacophore and also to compare AAI structures with those of classical cannabinoids. The fact that the cannabinoid AAIs arose out of work on a series of cyclooxygenase inhibitors make sense now that an endogenous cannabinoid ligand has been identified which is a derivative of arachidonic acid. Because of their unique structures and physical properties, AAIs provide useful tools to study the structure and function of the cannabinoid receptor(s).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636873     DOI: 10.1021/jm00016a013

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Severe toxicity following synthetic cannabinoid ingestion.

Authors:  J Lapoint; L P James; C L Moran; L S Nelson; R S Hoffman; J H Moran
Journal:  Clin Toxicol (Phila)       Date:  2011-10       Impact factor: 4.467

Review 2.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

Review 3.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 4.  Cannabinoid receptors: nomenclature and pharmacological principles.

Authors:  Linda Console-Bram; Jahan Marcu; Mary E Abood
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-28       Impact factor: 5.067

5.  Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.

Authors:  Herbert H Seltzman; Craig Shiner; Erin E Hirt; Anne F Gilliam; Brian F Thomas; Rangan Maitra; Rod Snyder; Sherry L Black; Purvi R Patel; Yatendra Mulpuri; Igor Spigelman
Journal:  J Med Chem       Date:  2016-08-10       Impact factor: 7.446

Review 6.  Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?

Authors:  Kathryn A Seely; Paul L Prather; Laura P James; Jeffery H Moran
Journal:  Mol Interv       Date:  2011-02

7.  7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.

Authors:  Narsimha Reddy Penthala; Amal Shoeib; Soma Shekar Dachavaram; Christian V Cabanlong; Jingfang Yang; Chang-Guo Zhan; Paul L Prather; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2020-08-31       Impact factor: 2.823

Review 8.  CB1 and CB2 Receptor Pharmacology.

Authors:  Allyn C Howlett; Mary E Abood
Journal:  Adv Pharmacol       Date:  2017-06-12

9.  1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.

Authors:  Jenny L Wiley; Julie A Marusich; Billy R Martin; John W Huffman
Journal:  Drug Alcohol Depend       Date:  2011-11-27       Impact factor: 4.492

10.  Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.

Authors:  Pietro Marini; Maria-Grazia Cascio; Angela King; Roger G Pertwee; Ruth A Ross
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.